Laurent Humeau
Chief Tech/Sci/R&D Officer bij INOVIO PHARMACEUTICALS, INC.
Vermogen: 295 214 $ op 31-03-2024
Profiel
Laurent M.
Humeau is currently the Director at Geneos Therapeutics, Inc. since 2022 and the Chief Scientific Officer at Inovio Pharmaceuticals, Inc. since 2014.
Previously, Dr. Humeau held positions as the Senior Director-Translational Research at Precigen, Inc. and as the Chief Scientific Officer & Vice President-Research at VIRxSYS Corp.
Dr. Humeau obtained an undergraduate and graduate degree from Université Pierre et Marie Curie and a doctorate degree from Université Paris Diderot-Paris 7.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 28-02-2024 | 21 269 ( 0.09% ) | 295 214 $ | 31-03-2024 |
Actieve functies van Laurent Humeau
| Bedrijven | Functie | Begin |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 18-02-2014 |
Geneos Therapeutics, Inc.
 Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Director/Board Member | 12-10-2022 |
Eerdere bekende functies van Laurent Humeau
| Bedrijven | Functie | Einde |
|---|---|---|
| PRECIGEN, INC. | Corporate Officer/Principal | - |
VIRxSYS Corp.
 VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Laurent Humeau
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
VIRxSYS Corp.
VIRxSYS Corp. BiotechnologyHealth Technology VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD. | Health Technology |
| Université Pierre et Marie Curie | Consumer Services |
| Université Paris Diderot-Paris 7 | Consumer Services |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Health Technology |
